Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Competition Commission...

    Competition Commission slaps Rs 72.96 crore penalty on Lupin

    Written by savita thakur thakur Published On 2016-08-02T11:34:13+05:30  |  Updated On 2 Aug 2016 11:34 AM IST
    Competition Commission slaps Rs 72.96 crore penalty on Lupin

    The Competition Commission of India (CCI) has imposed a penalty of Rs 72.96 crore on pharmaceutical company Lupin and Rs 8,60,321 on Karnataka Chemists and Druggist Association (KCDA) for anti-competitive practices, an official statement said here.


    "The Commission imposed a monetary penalty of Rs 8,60,321 calculated at the rate of 10 per cent of the average income of KCDA. It imposed a penalty at the rate of 1 per cent of Lupin's average turnover, amounting to Rs 72.96 crore," a finance ministry statement said.


    "In addition, monetary penalties were imposed on the office bearers of KCDA and officials of Lupin at the rate of 10 per cent and 1 per cent of their incomes, respectively," the statement said.


    Following a detailed investigation by the Commission, the KCDA was found indulging in the anti-competitive practice of mandating NOC (no objection certificate) prior to the appointment of new stockists by pharmaceutical companies, which has the effect of limiting and controlling of the supply of drugs in the market, it said.


    "The Commission also observed that the pharmaceutical companies cooperate with such associations to implement their anti-competitive decisions, thereby becoming equally complicit in the anti-competitive effect of such practice.


    "Instead of approaching the Commission, these pharmaceutical companies cooperate with the NOC requirement of the associations, thus becoming perpetrators of such anti-competitive practice," the statement said.


    The Commission has held Lupin responsible for its anti-competitive arrangement with KCDA, it said.

    CCIcommissionCompetition Commission of IndiaKarnataka Chemists and Druggist AssociationKCDALupinno objection certificateNOCpenalty
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok